ANA-KIN · Advancing Novel Approaches in Kinase Interface Networks
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-09-01 → 2030-08-31
- Финансиране от ЕС
- 3 563 532 €
- Участници
- 20
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.
Накратко на български
Протеиновите кинази се изследват чрез търсене на нови места за свързване на лекарства, вместо само в стандартния ATP център. Това помага за създаването на по-прецизни молекули, които да регулират работата на тези протеини по по-ефективен начин.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
ANA-KIN will train 12 doctoral researchers to redefine kinase drug discovery by pioneering strategies that move beyond the ATP site. Protein kinases are among the most validated drug targets, yet nearly all approved inhibitors still target the highly conserved ATP cleft, a 20-year-old paradigm that has seen remarkably little conceptual renewal. Dimerization and substrate interfaces, by contrast, are far less conserved and represent fundamentally different regulatory entry points. However, the field currently lacks the generalisable assays and cross-disciplinary integration needed to systematically exploit them.To address this, ANA-KIN establishes the first coordinated European framework dedicated to mapping and modulating kinase interfaces. It brings together leading expertise in chemical biology, structural biophysics, AI-guided design, PPI-focused discovery technologies and cellular mechanism across 12 academic laboratories and 10 academic and industrial partners. This integrated effort will produce ATP-locking chemical tools, modular interface-focused assays, high-resolution conformational maps and complementary bicyclic peptide/small-molecule discovery engines that collectively enable the systematic identification of interface-selective modulators.The training programme couples interdisciplinary co-supervision, intersectoral secondments and network-wide scientific schools with structured development in scientific, transferable, open-science and entrepreneurial skills. Robust governance (Supervision Oversight Board and Ombudsperson) ensures transparent supervision, while diversity and culture-of-care measures foster an inclusive and supportive environment.Through this coordinated research and training ecosystem, ANA-KIN will generate the tools, mechanistic foundations and interdisciplinary expertise required to unlock kinase interfaces as a new therapeutic frontier, while preparing a cohort capable of driving next-generation kinase drug discovery in Europe
Оригинален текст от CORDIS (на английски).
Участници
- ARISTOTELIO PANEPISTIMIO THESSALONIKIS · THESSALONIKIКоординаторГърция
- ASTRAZENECA UK LIMITED · CAMBRIDGEОбединеното кралство
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisФранция
- ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE · LausanneШвейцария
- ENZYQUEST PRIVATE COMPANY · HERAKLIONГърция
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisФранция
- JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN · Frankfurt Am MainГермания
- KATHOLIEKE UNIVERSITEIT LEUVEN · LeuvenБелгия
- NORTHEASTERN UNIVERSITY · Boston MaСъединени щати
- NOVARTIS PHARMA AG · BaselШвейцария
- PANEPISTIMIO KRITIS · RETHIMNOГърция
- SERVIER GYOGYASZATI VEGYTANI KUTATOINTEZET ZARTKORUEN MUKODO RESZVENYTARSASAG · BudapestУнгария
- Skylight Therapeutics BV · LeuvenНиво градБелгия
- THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordОбединеното кралство
- THE SCRIPPS RESEARCH INSTITUTE CORPORATION · LA JOLLAСъединени щати
- UNIVERSIDAD POMPEU FABRA · BarcelonaИспания
- UNIVERSITAT DES SAARLANDES · SaarbruckenГермания
- UNIVERSITE D'AIX MARSEILLE · MarseilleФранция
- UNIVERSITEIT LEIDEN · LeidenНидерландия
- VIB VZW · ZWIJNAARDE - GENTБелгия
Връзки
Данни: CORDIS, © Европейски съюз